GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

SXTP · Sep 30, 2024

60 DEGREES PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001213900-24-098195General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

110.87% · OPTIONAL · NOT_ENOUGH_HISTORY

Capex intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.capex_revenue_ratio

10.18% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-1242.65% · OPTIONAL · NOT_ENOUGH_HISTORY

Revenue growthRAWCurrent state valid · history insufficient

Evidence method

Yoy · gp.fundamentals.revenue

164.31% · CORE · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

334.12% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

17.45% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-1566.00% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

694.83% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

494.46% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History11 statesHistory building

Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/8 normalizedLevel 3 Sep 30, 20240/9 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20254/9 normalizedLevel 3 Sep 30, 20256/9 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20267/9 normalizedLevel 3 Jun 30, 20269/9 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Decreased

Previous: 120.03%
Current: 110.87%
Delta: -9.16%

Cash Generation Decreased

Previous: -950.78%
Current: -1242.65%
Delta: -291.87%

Growth Increased

Previous: 109.92%
Current: 164.31%
Delta: 54.38%

Inventory Pressure Decreased

Previous: 340.89%
Current: 334.12%
Delta: -6.78%

Margin Decreased

Previous: 28.33%
Current: 17.45%
Delta: -10.88%

Profitability Increased

Previous: -3351.75%
Current: -1566.00%
Delta: 1785.75%

R And D Intensity Decreased

Previous: 2476.82%
Current: 694.83%
Delta: -1781.98%

Sbc Intensity Decreased

Previous: 2202.63%
Current: 494.46%
Delta: -1708.16%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · SXTP Fundamental State →Transitioned To · SXTP Fundamental State →Transitioned To · SXTP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · SXTP CASH_GENERATION_DECREASED →Transitioned To · SXTP GROWTH_INCREASED →Transitioned To · SXTP INVENTORY_PRESSURE_DECREASED →Transitioned To · SXTP MARGIN_DECREASED →Transitioned To · SXTP PROFITABILITY_INCREASED →Transitioned To · SXTP R_AND_D_INTENSITY_DECREASED →Transitioned To · SXTP SBC_INTENSITY_DECREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.